Zhuhai Rundu Pharmaceutical Co., Ltd., commonly known as Rundu Pharma, is a prominent player in the pharmaceutical sector, operating under the broader health care industry. The company is listed on the Shenzhen Stock Exchange, where it trades under the currency of the Chinese Yuan (CNY). As of September 7, 2025, Rundu Pharma’s close price stood at 14.17 CNY. The company’s stock has experienced significant fluctuations over the past year, reaching a 52-week high of 19.56 CNY on April 2, 2025, and a 52-week low of 7.84 CNY on September 17, 2024. The market capitalization of Rundu Pharma is currently valued at 4,745,438,256 CNY.
Rundu Pharma specializes in the manufacturing and distribution of pharmaceuticals, focusing on chemical medicine preparations, pharmaceutical raw materials, and pharmaceutical intermediates. The company has established a robust distribution network, enabling it to market its products extensively throughout China. This strategic positioning allows Rundu Pharma to cater to a wide range of pharmaceutical needs across the nation, reinforcing its status as a key player in the Chinese pharmaceutical market.
The company’s operations are integral to the health care sector, contributing to the development and supply of essential pharmaceutical products. By focusing on both the production and distribution aspects, Rundu Pharma ensures a steady supply chain, which is crucial for meeting the demands of healthcare providers and patients alike. The company’s commitment to quality and innovation in pharmaceutical manufacturing underscores its role in advancing health care solutions within China.
As Rundu Pharma continues to navigate the dynamic pharmaceutical landscape, its performance on the Shenzhen Stock Exchange remains a critical indicator of its financial health and market perception. Investors and stakeholders closely monitor its stock movements, particularly in light of its recent price fluctuations, to gauge the company’s growth potential and stability in the competitive health care industry.